171 related articles for article (PubMed ID: 28658648)
1. Prevention of Human Lymphoproliferative Tumor Formation in Ovarian Cancer Patient-Derived Xenografts.
Butler KA; Hou X; Becker MA; Zanfagnin V; Enderica-Gonzalez S; Visscher D; Kalli KR; Tienchaianada P; Haluska P; Weroha SJ
Neoplasia; 2017 Aug; 19(8):628-636. PubMed ID: 28658648
[TBL] [Abstract][Full Text] [Related]
2. Rituximab Decreases Lymphoproliferative Tumor Formation in Hepatopancreaticobiliary and Gastrointestinal Cancer Patient-Derived Xenografts.
Leiting JL; Hernandez MC; Yang L; Bergquist JR; Ivanics T; Graham RP; Truty MJ
Sci Rep; 2019 Apr; 9(1):5901. PubMed ID: 30976061
[TBL] [Abstract][Full Text] [Related]
3. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
Loomis R; Carbone R; Reiss M; Lacy J
Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
[TBL] [Abstract][Full Text] [Related]
4. [Transformation of patient-derived tumor xenografts into lymphomas: characteristics, influence factors and precautions].
Zou J; Gao J; Shen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Jul; 19(7):833-7. PubMed ID: 27452762
[TBL] [Abstract][Full Text] [Related]
5. Rituximab Treatment Prevents Lymphoma Onset in Gastric Cancer Patient-Derived Xenografts.
Corso S; Cargnelutti M; Durando S; Menegon S; Apicella M; Migliore C; Capeloa T; Ughetto S; Isella C; Medico E; Bertotti A; Sassi F; Sarotto I; Casorzo L; Pisacane A; Mangioni M; Sottile A; Degiuli M; Fumagalli U; Sgroi G; Molfino S; De Manzoni G; Rosati R; De Simone M; Marrelli D; Saragoni L; Rausei S; Pallabazzer G; Roviello F; Cassoni P; Sapino A; Bass A; Giordano S
Neoplasia; 2018 May; 20(5):443-455. PubMed ID: 29574251
[TBL] [Abstract][Full Text] [Related]
6. Anti-CCR4 monoclonal antibody mogamulizumab for the treatment of EBV-associated T- and NK-cell lymphoproliferative diseases.
Kanazawa T; Hiramatsu Y; Iwata S; Siddiquey M; Sato Y; Suzuki M; Ito Y; Goshima F; Murata T; Kimura H
Clin Cancer Res; 2014 Oct; 20(19):5075-84. PubMed ID: 25117294
[TBL] [Abstract][Full Text] [Related]
7. Spectrum of Posttransplant Lymphoproliferations in NSG Mice and Their Association With EBV Infection After Engraftment of Pediatric Solid Tumors.
Tillman H; Vogel P; Rogers T; Akers W; Rehg JE
Vet Pathol; 2020 May; 57(3):445-456. PubMed ID: 32202225
[TBL] [Abstract][Full Text] [Related]
8. Favorable outcome of Epstein-Barr virus-associated B-cell lymphoproliferative disorder complicated by immunoglobulin G4-related disease treated with rituximab-based therapy: a case report.
Ueda K; Ikeda K; Ogawa K; Sukegawa M; Sano T; Kimura S; Suzuki O; Hashimoto Y; Takeishi Y
J Med Case Rep; 2016 Aug; 10(1):236. PubMed ID: 27557810
[TBL] [Abstract][Full Text] [Related]
9. [Molecular pathological characteristics of human B-cell lymphomas induced by Epstein-Barr virus].
Gan RL; Yin ZH; Liu TF; Dong BH; Zhou JG; Yao KT
Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Oct; 35(10):925-9. PubMed ID: 14515211
[TBL] [Abstract][Full Text] [Related]
10. Construction of hu-PBL/SCID chimeras and development of EBV-related lymphomas.
Gan RL; Lan K; Yin ZH; Wang LJ; Song Y; Yao KT
Chin Med Sci J; 2005 Mar; 20(1):16-22. PubMed ID: 15844306
[TBL] [Abstract][Full Text] [Related]
11. Characterization of Epstein-Barr virus-induced lymphoproliferation derived from human peripheral blood mononuclear cells transferred to severe combined immunodeficient mice.
Okano M; Taguchi Y; Nakamine H; Pirruccello SJ; Davis JR; Beisel KW; Kleveland KL; Sanger WG; Fordyce RR; Purtilo DT
Am J Pathol; 1990 Sep; 137(3):517-22. PubMed ID: 1975985
[TBL] [Abstract][Full Text] [Related]
12. Anti-CD20 monoclonal antibody (Rituximab) and Cidofovir as successful treatment of an EBV-associated lymphoma with CNS involvement.
Hänel M; Fiedler F; Thorns C
Onkologie; 2001 Oct; 24(5):491-4. PubMed ID: 11694778
[TBL] [Abstract][Full Text] [Related]
13. Patient-derived xenografts of gastrointestinal cancers are susceptible to rapid and delayed B-lymphoproliferation.
Dieter SM; Giessler KM; Kriegsmann M; Dubash TD; Möhrmann L; Schulz ER; Siegl C; Weber S; Strakerjahn H; Oberlack A; Heger U; Gao J; Hartinger EM; Oppel F; Hoffmann CM; Ha N; Brors B; Lasitschka F; Ulrich A; Strobel O; Schmidt M; von Kalle C; Schneider M; Weichert W; Ehrenberg KR; Glimm H; Ball CR
Int J Cancer; 2017 Mar; 140(6):1356-1363. PubMed ID: 27935045
[TBL] [Abstract][Full Text] [Related]
14. Experimental infection of NOD/SCID mice reconstituted with human CD34+ cells with Epstein-Barr virus.
Islas-Ohlmayer M; Padgett-Thomas A; Domiati-Saad R; Melkus MW; Cravens PD; Martin Mdel P; Netto G; Garcia JV
J Virol; 2004 Dec; 78(24):13891-900. PubMed ID: 15564497
[TBL] [Abstract][Full Text] [Related]
15. Tumor characteristics associated with engraftment of patient-derived non-small cell lung cancer xenografts in immunocompromised mice.
Chen Y; Zhang R; Wang L; Correa AM; Pataer A; Xu Y; Zhang X; Ren C; Wu S; Meng QH; Fujimoto J; Jensen VB; Antonoff MB; Hofstetter WL; Mehran RJ; Pisimisis G; Rice DC; Sepesi B; Vaporciyan AA; Walsh GL; Swisher SG; Roth JA; Heymach JV; Fang B
Cancer; 2019 Nov; 125(21):3738-3748. PubMed ID: 31287557
[TBL] [Abstract][Full Text] [Related]
16. Plasmacytic hyperplasia in age-related Epstein-Barr virus-associated lymphoproliferative disorders: a report of two cases.
Kojima M; Morita Y; Nakamura N; Shimizu K; Murayama K; Nakamura S
Pathol Res Pract; 2008; 204(4):267-72. PubMed ID: 18187262
[TBL] [Abstract][Full Text] [Related]
17. Imatinib mesylate reduces rituximab-induced tumor-growth inhibition in vivo on Epstein-Barr virus-associated human B-cell lymphoma.
Némati F; Mathiot C; Grandjean I; Lantz O; Bordier V; Dewulf S; Ekue R; Di Santo JP; Poupon MF; Decaudin D
Anticancer Drugs; 2007 Oct; 18(9):1029-37. PubMed ID: 17704653
[TBL] [Abstract][Full Text] [Related]
18. Expression of LMP and EBNA genes in Epstein-Barr virus-associated lymphomas in Hu-PBL/SCID mice.
Tang Y; Lu S; Gan X; Liu F; Zhang Y; Luo C; Pan Y; Hong L; Gan R
Oncol Rep; 2016 Feb; 35(2):905-11. PubMed ID: 26548532
[TBL] [Abstract][Full Text] [Related]
19. Pre-emptive rituximab based on viraemia and T cell reconstitution: a highly effective strategy for the prevention of Epstein-Barr virus-associated lymphoproliferative disease following stem cell transplantation.
Worth A; Conyers R; Cohen J; Jagani M; Chiesa R; Rao K; Goulden N; Veys P; Amrolia PJ
Br J Haematol; 2011 Nov; 155(3):377-85. PubMed ID: 21910716
[TBL] [Abstract][Full Text] [Related]
20. [Post-transplant lymphoproliferative disorder: a clinicopathologic study of 15 cases].
Chen DB; Wang Y; Song QJ; Shen DH
Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):607-12. PubMed ID: 23157829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
